← Back to Clinical Trials
Recruiting NCT06089096

NCT06089096 Sleep Apnea and Cognitive Function in Subjects With Subjective or Mild Cognitive Impairment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06089096
Status Recruiting
Phase
Sponsor The University of Hong Kong
Condition Obstructive Sleep Apnea
Study Type OBSERVATIONAL
Enrollment 250 participants
Start Date 2023-03-07
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Home Sleep Apnea test (HSAT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 250 participants in total. It began in 2023-03-07 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Obstructive sleep apnea (OSA) is recurrent episodes of partial or complete obstruction of the upper airway during sleep that causes intermittent hypoxia and sleep fragmentation and leads to cardiometabolic and neurocognitive sequelae. Chronic intermittent hypoxia, sleep fragmentation of OSA, and insufficient sleep have been significantly associated with higher risks of neurocognitive impairment, including mild cognitive impairment (MCI) and Alzheimer's disease. Thus, sleep and circadian function might be modifiable neurocognitive impairment factors. The significance of the study is to understand the relationships of MCI with sleep apnea and sleep-related symptoms, which helps pave the groundwork for further research.

Eligibility Criteria

Inclusion Criteria: * Aged 18 years and above * Clinical diagnosis of mild cognitive impairment (MCI) based on Petersen's criteria. The criteria include the following: (1) memory problems, (2) objective memory disorder, (3) absence of other cognitive disorders or repercussions on daily life, (4) normal general cognitive function and (5) absence of dementia OR, * Diagnosis of subjective cognitive impairment, based on the subject's own complaint of cognitive impairment but with an unremarkable assessment of the Hong Kong version of Montreal Cognitive Assessment scores * Able to speak and read Chinese * Adequate visual and auditory to perform a cognitive test Exclusion Criteria: * Diagnosed psychiatric illness with or without medication, e.g. major depressive disorder. * Other clear organic causes of cognitive impairment, e.g. old stroke, brain tumour, dementia with Lewy body, Parkinson's disease, normal pressure hydrocephalus, neurosyphilis, autoimmune encephalitis, substance abuse, history of alcohol abuse. * Diagnosis of major unstable illness or cancer on active treatment * Unable to perform Home Sleep Apnea Test * Those patients who require legal guardians

Contact & Investigator

Central Contact

Sau Man Mary Ip, MD

✉ msmip@hku.hk

📞 2255 5885

Principal Investigator

Sau Man Mary Ip, MD

PRINCIPAL INVESTIGATOR

School of Clinical Medicine, The University of Hong Kong

Frequently Asked Questions

Who can join the NCT06089096 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Obstructive Sleep Apnea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06089096 currently recruiting?

Yes, NCT06089096 is actively recruiting participants. Contact the research team at msmip@hku.hk for enrollment information.

Where is the NCT06089096 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT06089096 clinical trial?

NCT06089096 is sponsored by The University of Hong Kong. The principal investigator is Sau Man Mary Ip, MD at School of Clinical Medicine, The University of Hong Kong. The trial plans to enroll 250 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology